Form 4 Filing for Celldex Therapeutics, Inc. - Insider Transaction

Diane C. Young, SVP, Chief Medical Officer of Celldex Therapeutics, Inc. (CLDX), was granted 57,000 Incentive Stock Options on June 25, 2026. These options have an exercise price of $34.09 and will expire on June 25, 2036. The options vest over a period of approximately 3.25 years, with 25% vesting on June 25, 2027, and the remainder vesting quarterly over the subsequent 12 quarters. This transaction is reported on Form 4, indicating an insider transaction.